| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.9 |